Nabi readies study for NicVAX

Nabi Biopharmaceuticals of Rockville, MD says that it is ready to launch a Phase II proof-of-concept study for NicVAX, designed to help smokers give up the habit and stay off nicotine. The study is also designed to give researchers a better understanding of the optimal dose for the Phase III trial.

- read this release for more information

ALSO: Nabi announced that its senior vice president for global sales and marketing, H. LeRoux Jooste, has been terminated effective Feb. 28. Report